AbbVie (NYSE:ABBV) Announces FY 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its FY 2026 earnings guidance on Tuesday. The company provided earnings per share guidance of 13.950-13.990 for the period, compared to the consensus EPS estimate of 13.950. The company issued revenue guidance of $67.8 billion, compared to the consensus revenue estimate of $67.6 billion. AbbVie also updated its Q4 2026 guidance to 3.830-3.870 EPS.

Analyst Ratings Changes

ABBV has been the subject of a number of recent research reports. UBS Group upped their price target on AbbVie from $275.00 to $295.00 and gave the stock a “neutral” rating in a research report on Monday. Rothschild & Co Redburn lifted their price objective on shares of AbbVie from $284.00 to $285.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Guggenheim boosted their price objective on shares of AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a research report on Monday. Cantor Fitzgerald boosted their price objective on shares of AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and increased their target price for the stock from $235.00 to $300.00 in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $294.67.

AbbVie Stock Down 0.2%

Shares of NYSE:ABBV traded down $0.72 during midday trading on Tuesday, reaching $288.12. The company had a trading volume of 1,008,782 shares, compared to its average volume of 6,315,951. AbbVie has a 1-year low of $190.75 and a 1-year high of $298.74. The stock has a market cap of $509.05 billion, a PE ratio of 49.59, a P/E/G ratio of 1.31 and a beta of 0.24. The business’s 50 day moving average price is $269.81 and its 200 day moving average price is $237.57.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. The firm had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.86 earnings per share. On average, research analysts expect that AbbVie will post 13.92 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. The ex-dividend date is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio (DPR) is currently 119.10%.

Insider Activity at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at approximately $18,607,500. This represents a 30.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie raised its fiscal 2026 revenue outlook to $67.8 billion, above the $67.6 billion consensus, and set full-year adjusted EPS guidance of $13.95-$13.99. Q3 revenue increased 10.3% year over year to $17.4 billion, while adjusted EPS of $3.82 exceeded estimates. ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress
• Positive Sentiment: Analysts responded by raising price targets, including Morgan Stanley to $346, Leerink Partners to $342, RBC to $330, Canaccord Genuity to $338 and Cantor Fitzgerald to $325, generally retaining positive ratings. Analysts Increase Forecasts on AbbVie
• Positive Sentiment: AbbVie expanded its global migraine-drug licensing partnership with Brise Pharmaceuticals. The agreement could be worth up to approximately $757 million and adds another potential growth asset to the neuroscience pipeline. AbbVie License Deal With Brise Potentially Valued at $757 Million
• Positive Sentiment: AbbVie won a lawsuit against the Department of Health and Human Services related to drug-price controls, potentially reducing near-term regulatory pricing pressure. The company also reported positive Phase 3 migraine-study news and continues to advance promising immunology candidates.
• Positive Sentiment: Allergan Aesthetics will present nine research abstracts at ASDS 2026, including studies involving post-medical-weight-loss aesthetic care and investigational trenibotulinumtoxinE, supporting AbbVie’s aesthetics pipeline and scientific positioning. Allergan Aesthetics Research at ASDS 2026
• Neutral Sentiment: AbbVie increased its quarterly dividend 5.2% to $1.82 per share, or $7.28 annualized, reinforcing its appeal to income-oriented investors.
• Negative Sentiment: Fourth-quarter revenue guidance of $18.4 billion is slightly above consensus, but adjusted EPS guidance of $3.83-$3.87 is below the $3.89 analyst estimate. In addition, shares have already gained roughly 33% this year and trade at a rich valuation, leaving less room for execution missteps. AbbVie Hit a New High After Earnings

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.